Browse regulations

This regulation repeals the Ombudsman (Northern Territory Self-Government) (Transitional Arrangements) regulations, which had governed the transition arrangements dating from when the Northern Territory gained self-government. The instrument simplifies the regulatory framework by removing these obsolete, long-expired transitional provisions.

Deleting this instrument would reinstate obsolete transitional arrangements from the NT self-government era that have long since served their purpose. This repeal is deregulatory in nature, reducing regulatory clutter and eliminating anachronistic provisions that no longer serve any legitimate function. Australians are better off with this redundant legislation removed, as it simplifies compliance and reduces unnecessary legal complexity without removing any substantive protections.

Unable to locate the actual text of this instrument. Based on metadata, this appears to be a 2012 amendment to Australian Crime Commission regulations, which govern the ACC's coordination of federal and state/territory law enforcement intelligence and operations. ACC regulations typically cover operational matters, inter-agency information sharing, and law enforcement procedures rather than business compliance requirements.

The Australian Crime Commission regulates law enforcement coordination, not business activities. Without the specific text, I cannot identify provisions imposing economic compliance costs. However, even if found, law enforcement coordination regulations are distinct from the economic regulatory burdens (mining approvals, housing, occupational licensing, nanny state overreach) that are the primary targets for deletion under the Better Australia framework. The ACC's coordination role addresses genuine public safety needs that market mechanisms cannot readily solve, and its regulations do not typically restrict business creation, employment, or property rights in the manner of the regulations this framework targets for elimination.

Amends the Trade Practices (Industry Codes - Oilcode) Regulations 2006, which regulated commercial relationships in the oil industry between major oil companies and independent service station operators, including fuel supply agreements, terminal gate pricing, and site ownership arrangements.

Industry codes like the Oilcode restrict freedom of contract and interfere with market signals. They impose compliance costs that disproportionately burden smaller operators and can protect inefficient incumbents from competition. Without the actual 2012 amendment text, the inherent regulatory framework of the Oilcode itself represents a cost on commerce that would not exist in a truly free market. Competition law already addresses misuse of market power; dedicated industry codes create overlapping, redundant, and distortive regulation that harms long-term prosperity and competitiveness.

Australian federal regulation that amended the Renewable Energy (Electricity) Regulations 2001, forming part of the Renewable Energy Target (RET) scheme. It modified requirements around large-scale renewable energy certificates (LGCs), small-scale technology certificates (STCs), and associated compliance mechanisms for electricity retailers and generators.

Mandated renewable energy quotas distort the electricity market by artificially constraining supply options and raising costs through certificate trading schemes. The RET framework creates billions in compliance costs that flow through to electricity prices, harming households and businesses—particularly energy-intensive industries. It picks winners in the energy sector rather than allowing market discovery. Government-mandated renewable targets are a blunt instrument that cannot efficiently direct capital compared to private property rights and voluntary exchange. The unintended consequences include reduced grid reliability, higher spot prices, and capital misallocation toward intermittent generation sources that require backup capacity.

Amends the A New Tax System (Goods and Services Tax) Regulations 1999 to modify GST treatment for certain goods, services, or entities, likely making technical or substantive changes to compliance requirements, exemptions, or definitional matters under Australia's 10% consumption tax framework.

The GST regime represents government coercion in the market, distorting consumer prices and imposing compliance burdens on businesses. This amendment regulation, by its nature of modifying GST rules, likely adds complexity, compliance costs, or expands the scope of taxation. From a Mises/Hayek/Friedman perspective, consumption taxes distort market signals, harm low-income Australians disproportionately, and create barriers to economic freedom. The unseen costs include reduced consumer choice, distorted investment decisions, and the ongoing compliance apparatus that drains resources better deployed in productive activities.

Amends the Aviation Transport Security Regulations 2005 to modify security requirements for aviation transport, including adjustments to screening procedures, secure area access controls, and related compliance obligations for airports and air carriers.

Aviation security regulations impose substantial compliance costs on airlines, airports, and passengers through mandatory screening procedures, secure zone designations, and documentation requirements. These costs are passed on to travelers and reduce aviation sector competitiveness. Security measures often constitute 'security theater' with questionable effectiveness—the 2012 amendments likely added layer upon layer of requirements without robust evidence of reduced risk. Genuine security outcomes can be better achieved through market mechanisms, private security innovation, and risk-based approaches rather than prescriptive government mandates. The regulation also compounds compliance burdens through federal-state duplication.

This regulation amended the Medicare Benefits Schedule (MBS) General Medical Services Table, modifying fees, item descriptors, and benefit structures for medical services. It represents one of many annual or semi-annual updates to the regulated prices for health services, affecting what doctors can charge patients and what Medicare rebates are payable.

This instrument exemplifies centralized price scheduling of medical services, which distorts healthcare markets by: (1) creating artificial scarcity of services with low rebate levels, contributing to out-of-pocket cost growth; (2) generating rent-seeking as medicalpeak bodies lobby for favorable item inclusions; (3) reducing incentives for innovation in service delivery since new methods must be schedulized to attract rebates; (4) fragmenting care through siloed item numbers rather than allowing integrated billing models. The compliance burden on practitioners is substantial—navigating thousands of MBS items with complex rules and processing requirements. Australia's health system would benefit from deregulation allowing competitive pricing, portable entitlements, and consumer-directed care rather than centralized command-and-control scheduling. Repeal would allow market prices to emerge, increasing supply responsiveness and reducing administrative compliance costs borne by medical practices.

Amends the Health Insurance Regulations 1975, likely modifying private health insurance rebate calculations, Medicare Levy Surcharge thresholds, Lifetime Health Cover provisions, or health insurer compliance requirements under the Private Health Insurance Act 2007.

Regulations governing private health insurancerebates and related provisions distort the health insurance market, create compliance costs for insurers that are passed on to consumers, and represent government coercion in healthcare financing decisions. Such regulations should be deleted to allow more competitive and consumer-driven health insurance markets.

The Coastal Trading (Revitalising Australian Shipping) Regulation 2012 regulates domestic commercial shipping between Australian ports under the Coastal Trading (Revitalising Australian Shipping) Act 2012. It establishes a licensing regime requiring vessels engaged in coastal trading to hold licences, imposes Australian content requirements, restricts foreign vessel participation in coastal trade, and creates compliance obligations for shipping operators. The stated purpose is to support and revitalise Australia's domestic maritime industry.

This regulation creates licensing barriers that restrict competition in coastal shipping, protects incumbent operators from foreign competition, and adds compliance costs that are passed to Australian businesses and consumers. It exemplifies the classic regulatory failure of attempting to preserve an industry through restrictions rather than allowing market forces to determine efficient outcomes. The Australian mining and resources sector—which depends on efficient coastal freight transport—would benefit from competitive, unencumbered shipping markets. Such licensing regimes historically distort incentives, reduce supply, increase costs, and serve to protect established players rather than consumers or the broader economy. Genuine maritime safety and environmental goals can be achieved through targeted, less restrictive measures.

Amends the Therapeutic Goods (Medical Devices) Regulation 2002 to modify requirements for medical device conformity assessment, clinical evidence, and registration processes under the Therapeutic Goods Act 1989. Introduces changes to device classification, Essential Principles compliance, and post-market monitoring obligations.

Medical devices represent a category where information asymmetry between manufacturers and patients is extreme, and device failures can cause irreversible harm or death. Without regulatory oversight of device safety and efficacy, Australians would face substantially higher risks from faulty implants, diagnostic equipment, and therapeutic devices. While the TGA system is not perfect, the coordination problem of ensuring consistent safety standards across all devices and manufacturers cannot be adequately addressed through private certification alone. The potential costs of removing this framework—increased patient harm, litigation, and loss of confidence in medical treatment—would significantly exceed the compliance costs of the current regime.

Amends the Therapeutic Goods (Medical Devices) Regulations 2002 to modify requirements for medical device compliance, including changes to conformity assessment procedures, post-market surveillance, and technical documentation requirements for therapeutic goods administered by the TGA.

Medical device regulation adds substantial compliance costs that are ultimately borne by patients and the healthcare system. Approval timelines for devices can delay access to innovative treatments. While some oversight is warranted, this amendment layer adds further red tape without clear evidence of improved patient outcomes. The TGA's overlapping requirements with international regulators (FDA, CE marking) create duplicative compliance burdens for manufacturers, raising device costs. Australians would benefit more from mutual recognition of international approvals than additional domestic regulatory layers.

Amendment to Therapeutic Goods (Charges) Regulations that modified fee structures for therapeutic goods sponsors, manufacturers, and importers under the Therapeutic Goods Act 1989. Imposes annual registration charges, evaluation fees, and other cost recovery charges to fund TGA operations.

Without access to the specific 2012 amendment text, I cannot fully assess its provisions. However, charges regulations for therapeutic goods impose costs on the pharmaceutical industry that are passed to consumers, reducing access to medicines and competitiveness. Government-mandated cost recovery charges, while funding legitimate regulatory functions, should be minimized. The underlying therapeutic goods safety regulation can function through general taxation or significantly reduced fees. Additionally, regulatory charges disproportionately burden smaller pharmaceutical enterprises and startups, reducing innovation and market entry.

Amendment to the Therapeutic Goods (Charges) Regulations that modifies fees and charges related to therapeutic goods including medicines, medical devices, and biologicals. The amendment would alter registration fees, evaluation charges, annual listing fees, and other cost-recovery measures for TGA regulatory activities.

Regulatory charges on therapeutic goods act as a hidden tax that increases costs for businesses, reduces competitiveness, and creates barriers to entry for smaller operators. The TGA's regulatory functions could be funded through general taxation rather than industry-specific charges that distort market incentives. Without the specific amendment text, I cannot confirm this amendment reduced charges, but regulatory charge amendments historically trend upward, adding cumulative compliance burden. The therapeutic goods sector would benefit from reduced regulatory charges that currently discourage innovation and market competition, potentially raising prices for consumers and limiting choices.

Therapeutic Goods Amendment Regulation 2012 (No. 2) is a fee amendment instrument that increased various registration, evaluation, and application fees under the Therapeutic Goods Regulations 1990 by approximately 3-6%. It amended Schedule 9 and Schedule 9A to update dozens of fee items for therapeutic goods, medical devices, and related regulatory services, commencing 1 July 2012.

This regulation does nothing to reduce regulatory burden or improve competitiveness—it solely increases compliance costs on therapeutic goods businesses through fee hikes averaging 3-6% across dozens of fee items. Higher fees create barriers to entry for smaller market participants, reduce competition, and are passed on to consumers. From a Mises/Hayek/Friedman perspective, this is pure rent-seeking behavior that adds no value while distorting market incentives. The fees had been increasing for years, contributing to Australia's high therapeutic goods compliance costs. The instrument has already expired (2012-2014) so repeal would have no practical effect other than preventing any potential future revival.

Amendment to Therapeutic Goods Regulations 1990, registered June 2012, made modifications to the regulatory framework governing therapeutic goods including medicines, medical devices, and biologicals.

Cannot access actual content to assess specific provisions. As a 2012 amendment to the Therapeutic Goods Regulations 1990 (principal instrument), it has been superseded by subsequent amendments over the past 15+ years. Regardless of content, amendments of this age are typically incorporated into consolidated principal instruments. Furthermore, therapeutic goods regulation represents a significant compliance burden on the healthcare sector, with TGA approval processes adding substantial costs and delays to bringing medicines and medical devices to market, often with questionable net benefit to consumers.